Literature DB >> 16843517

Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line.

Kyeong-Ok Chang1, Stanislav V Sosnovtsev, Gaël Belliot, Adriene D King, Kim Y Green.   

Abstract

Norwalk virus (NV) is a prototype strain of the genus Norovirus in the family Caliciviridae. The human noroviruses have emerged as major agents of acute gastroenteritis in all age groups, but there are no vaccines or antiviral agents partly due to the absence of a cell culture system. We report the generation of cells expressing self-replicating NV RNA (NV replicon) following transfection of NV RNA bearing an engineered neomycin resistance gene into cell lines of human (Huh-7) or hamster (BHK21) origin. Expression of replicon RNA was significantly reduced in the presence of interferon (IFN)-alpha in a dose-dependent manner in the NV replicon-bearing cells, suggesting a role for innate immunity in the control of human norovirus replication. This stable NV replicon system should lead to new insights into norovirus replication, virus-host interactions, and approaches for the treatment of norovirus disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16843517     DOI: 10.1016/j.virol.2006.06.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  97 in total

1.  The murine norovirus core subgenomic RNA promoter consists of a stable stem-loop that can direct accurate initiation of RNA synthesis.

Authors:  Muhammad Amir Yunus; Xiaoyan Lin; Dalan Bailey; Ioannis Karakasiliotis; Yasmin Chaudhry; Surender Vashist; Guo Zhang; Lucy Thorne; C Cheng Kao; Ian Goodfellow
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Cyclosulfamide-based derivatives as inhibitors of noroviruses.

Authors:  Dengfeng Dou; Sivakoteswara R Mandadapu; Kevin R Alliston; Yunjeong Kim; Kyeong-Ok Chang; William C Groutas
Journal:  Eur J Med Chem       Date:  2011-10-20       Impact factor: 6.514

3.  Model systems for the study of human norovirus Biology.

Authors:  S Vashist; D Bailey; A Putics; I Goodfellow
Journal:  Future Virol       Date:  2009-07       Impact factor: 1.831

4.  Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication.

Authors:  Larissa B Thackray; Erning Duan; Helen M Lazear; Amal Kambal; Robert D Schreiber; Michael S Diamond; Herbert W Virgin
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

Review 5.  Treatment of norovirus infections: moving antivirals from the bench to the bedside.

Authors:  Stuart S Kaufman; Kim Y Green; Brent E Korba
Journal:  Antiviral Res       Date:  2014-02-25       Impact factor: 5.970

6.  Type I and type II interferons inhibit the translation of murine norovirus proteins.

Authors:  Harish Changotra; Yali Jia; Tara N Moore; Guangliang Liu; Shannon M Kahan; Stanislav V Sosnovtsev; Stephanie M Karst
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

7.  Antiviral activity of Schizonepeta tenuifolia Briquet against noroviruses via induction of antiviral interferons.

Authors:  Yee Ching Ng; Ye Won Kim; Jeong-Su Lee; Sung Joon Lee; Moon Jung Song
Journal:  J Microbiol       Date:  2018-08-23       Impact factor: 3.422

Review 8.  Viruses in Rodent Colonies: Lessons Learned from Murine Noroviruses.

Authors:  Stephanie M Karst; Christiane E Wobus
Journal:  Annu Rev Virol       Date:  2015-07-02       Impact factor: 10.431

9.  Role of cholesterol pathways in norovirus replication.

Authors:  Kyeong-Ok Chang
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

10.  Functional analysis of RNA structures present at the 3' extremity of the murine norovirus genome: the variable polypyrimidine tract plays a role in viral virulence.

Authors:  Dalan Bailey; Ioannis Karakasiliotis; Surender Vashist; Liliane Man Wah Chung; Jivan Rees; Jivan Reese; Nora McFadden; Alicia Benson; Felix Yarovinsky; Peter Simmonds; Ian Goodfellow
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.